Luke Evnin Sells 39,560 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 39,560 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $0.93, for a total transaction of $36,790.80. Following the completion of the sale, the director owned 3,552,501 shares of the company’s stock, valued at $3,303,825.93. This represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $34,789.95.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $40,832.52.
• On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $36,782.96.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $77,876.01.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock traded up $0.00 during mid-day trading on Monday, hitting $0.92. 519,418 shares of the company were exchanged, compared to its average volume of 503,244. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The business has a fifty day moving average of $1.57 and a 200 day moving average of $1.34. The company has a market capitalization of $44.63 million, a PE ratio of -0.57 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently modified their holdings of HOWL. Charles Schwab Investment Management Inc. boosted its stake in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares during the last quarter. MPM Asset Management LLC increased its stake in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC raised its holdings in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the period. Nuveen LLC bought a new position in shares of Werewolf Therapeutics during the first quarter worth $71,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on HOWL. Bank of America reduced their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities reduced their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Finally, Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.